Recent advances using anti-CTLA-4 for the treatment of melanoma.
about
Genetic engineering with T cell receptorsNovel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.Vaccines against human carcinomas: strategies to improve antitumor immune responses.Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Targeting inhibitory pathways in cancer immunotherapy.Monoclonal antibodies: versatile platforms for cancer immunotherapy.Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenanceRegulatory T cells in HIV immunotherapyDifferential expression patterns of capping protein, protein phosphatase 1, and casein kinase 1 may serve as diagnostic markers for malignant melanomaVaccines and future global health needs.Treating cancer with genetically engineered T cells.Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in miceIrradiation of donor mononuclear cells for treatment of chemorefractory metastatic solid cancers: a community-based immune transplant pilot studyGene-expression profiling in vaccine therapy and immunotherapy for cancerFunctional anatomy of T cell activation and synapse formation.Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.Tumor evasion from T cell surveillance.Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.
P2860
Q26995677-DCDFB79A-702B-438F-BBF5-C1ED9F97494DQ33565239-5A94B22C-449E-45E6-8242-D234E6DD7A23Q33734281-AF48FFBD-C95E-45BF-8112-9FB82E755093Q33783032-532F31AF-2A7B-4B56-A1A4-18B151FC65C3Q33903025-D422B8FE-8030-4405-86BE-F246BF008EF5Q33950640-94486D67-0C8F-4CD1-BD70-DE1CC46603C5Q34111693-A4D8B7B6-0BAD-4F62-81BF-E7AB914097D9Q34472025-6EAE51B3-F9F3-4C23-B0E7-88D8505D3A91Q34725547-08603E66-598E-4A15-A5AA-382E3A33B2ECQ35091246-472B3A7F-A007-46C4-82DA-763DE8FF24ADQ35137122-96D03E1E-F51B-4DBC-8E7A-9925D66D2EB0Q35353365-340F3FFF-D24A-45A0-A810-0A7D1077FDE8Q35370005-5B9FED80-4EFD-4F21-953C-B143368D6787Q36089567-B22B1384-0B55-4AC9-9458-71D38CBE033AQ36138329-1FCB996E-4F07-466F-8523-B1883E6BF94AQ37646737-54F497BD-739A-42F7-AD3C-98690BD56B57Q37809156-9ABE48F7-62B8-40D7-AB1B-19B9510FE957Q37970674-5E7055D5-0532-417E-8B5C-CAF14882AFF9Q38223355-9CD0E7D9-6270-45BC-BF7A-21C9A0EE109BQ41883987-EB90BAF3-8BE7-4E11-A4AA-7BB7F12C454DQ47547580-E7232EC7-4837-4A0C-BFD2-CB36A8CA5FF3
P2860
Recent advances using anti-CTLA-4 for the treatment of melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent advances using anti-CTLA-4 for the treatment of melanoma.
@en
Recent advances using anti-CTLA-4 for the treatment of melanoma.
@nl
type
label
Recent advances using anti-CTLA-4 for the treatment of melanoma.
@en
Recent advances using anti-CTLA-4 for the treatment of melanoma.
@nl
prefLabel
Recent advances using anti-CTLA-4 for the treatment of melanoma.
@en
Recent advances using anti-CTLA-4 for the treatment of melanoma.
@nl
P1433
P1476
Recent advances using anti-CTLA-4 for the treatment of melanoma.
@en
P2093
Amod A Sarnaik
Jeffrey S Weber
P304
P356
10.1097/PPO.0B013E3181A7450F
P577
2009-05-01T00:00:00Z